Establishing Reliable Pancreatic Cancer Xenograft Models in Preclinical Research
Pancreatic ductal adenocarcinoma (PDAC) is characterized by an extensive desmoplastic stroma, hypoxic microregions, and early metastatic spread, making orthotopic transplantation under the pancreatic capsule the gold standard for preclinical modeling. Subcutaneous xenografts fail to replicate these critical aspects. Altogen Labs uses authenticated human PDAC lines—such as PANC-1, MIA PaCa-2, BxPC-3, AsPC-1, and Capan-1—to establish orthotopic pancreatic xenografts in NOD/SCID mice.
The procedure begins with expansion of tumor cells to 70–80% confluence in culture, followed by resuspension of 1 × 10^6 cells in a 1:1 mixture of serum-free medium and high-concentration Matrigel, which mimics the extracellular matrix and promotes initial cell adhesion. Mice (6–8 weeks old) are anesthetized, and a small left lateral laparotomy is performed to expose the pancreas. Using a 30-gauge needle, the cell–Matrigel suspension is delivered (20 µL) directly beneath the splenic lobe of the pancreas, ensuring minimal leakage. The peritoneum and skin are closed, and mice receive analgesia. Tumor take rates exceed 90%, and palpable tumors appear within 10–14 days.
Orthotopic implants develop robust desmoplastic stroma, recapitulating PDAC’s hallmark collagen-rich environment, as confirmed by Masson’s trichrome staining. Hypoxia markers—pimonidazole and HIF1α—are prominently expressed by Day 21. Altogen Labs monitors tumor growth using high-frequency ultrasound imaging, allowing volumetric measurements without sacrificing animals. Tumor volume (V) is calculated as (length × width^2)/2, where length and width are measured in millimeters. At designated endpoints (typically 200–300 mm³), tumors are harvested and sectioned for histopathologic analysis, including immunohistochemistry for CA19-9, CK19, and Ki-67, verifying epithelial origin and proliferation status.
Orthotopic models also facilitate metastatic studies: PANC-1 xenografts demonstrate liver and peritoneal seeding by Day 28, while MIA PaCa-2 xenografts tend to metastasize to lung. Genomic profiling of harvested metastases shows maintenance of driver mutations (e.g., KRAS^G12D, TP53^R273H), underscoring model fidelity. For therapeutic evaluation, Altogen Labs integrates in vivo transfection: PANC-1 cells pre-transfected with firefly luciferase using Altogen’s in vitro reagents ensure sensitive bioluminescent tracking. Upon systemic delivery of siRNA targeting KRAS, in vivo imaging reveals a 50% decrease in luminescence signal in orthotopic tumors at 48 hours, correlating with qRT-PCR–confirmed mRNA knockdown.
Altogen Labs also offers patient-derived xenograft (PDX) services, implanting tumor fragments from surgical specimens under the pancreatic capsule. These PDX models preserve tumor heterogeneity, including stromal and immune components, as evidenced by human stromal fibroblast markers (α-SMA) and infiltrating CD68+ macrophages. Drug efficacy studies using gemcitabine or nanoparticle-delivered siRNA combinations demonstrate clinical concordance; PDX models from gemcitabine-resistant patients similarly exhibit resistance, whereas sensitive PDXs respond with >60% tumor regression. By providing robust orthotopic and PDX models, Altogen Labs ensures that preclinical findings closely predict human outcomes.